Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?

Nephrology Dialysis Transplantation

Volumn 24, Issue 2, 2009, Pages 338-341

  Haneda, Masakazu ^a   Morikawa, Akizuki ^b  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b ASAHIKAWA RED CROSS HOSPITAL   (Japan)

Author keywords

Diabetes mellitus; Diabetic nephropathy; Glycated albumin; HbA1c; Hypoglycaemia

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; EXCENATIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLYBRIDE; INSULIN; METFORMIN; MIGLITOL; MITIGLINIDE; NATEGLINIDE; PIOGLITAZONE; RAPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VOGLIBOSE;

CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SIDE EFFECT;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY FAILURE, CHRONIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 58449085258     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn616     Document Type: Conference Paper

References (28)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes. N Engl J Med 1993; 329: 977-986
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865
4. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117
5. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
6. Gaede P, Vedel P, Parving HH et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622
7. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes. A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972
8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471
9. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008; 31(Suppl 1): S12-S54
10. Kahn SE, Haffner SM, Heise MA et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443
11. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258
12. Butler AE, Janson J, Bonner-Weir S et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110
13. Alaveras AE, Thomas SM, Sagriotis A et al. Promoters of progression of diabetic nephropathy: the relative roles of blood glucose and blood pressure control. Nephrol Dial Transplant 1997; 12(Suppl 2): 71-74
14. Oomichi T, Emoto M, Tabata T et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006; 29: 1496-1500
15. Kalantar-Zadeh K, Kopple JD, Regidor DL et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care 2007; 30: 1049-1055
16. Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis 2007; 50: 865-879
17. Harrower AD. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 1996; 31: 111-119
18. KDOQI Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Guideline 2: Management of hyperglycemia and general diabetes care in chronic kidney disease. Am J Kidney Dis 2007; 49(Suppl 2): S62-S73
19. Bergman AJ, Cote J, Yi B et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007; 30: 1862-1864
20. Agrawal A, Sautter MC, Jones NP. Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis. Clin Ther 2003; 25: 2754-2764
21. Budde K, Neumayer HH, Fritsche L et al. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003; 55: 368-374
22. Aronoff GR, Berns JS, Brier ME et al. (eds). Drug prescribing in renal failure. Dosing Guidelines for Adults. 4th edn. Philadelphia: American College of Physicians, 1999, p 84
23. Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000; 26: 73-85
24. Hayashino Y, Fukuhara S, Akiba T et al. Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan dialysis outcomes and practice pattern study. Diabetologia 2007; 50: 1170-1177
25. Inaba M, Okuno S, Kumeda Y et al. Osaka CKD Expert Research Group. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007; 18: 896-903
26. Peacock TP, Shihabi ZK, Bleyer AJ et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 2008; 73: 1062-1068
27. Fukuoka K, Nakao K, Morimoto H et al. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology 2008; 13: 278-283
28. Imai E, Horio M, Nitta K et al. Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis 2007; 50: 927-937